| 1 |
He Y,Zheng R,Li D, et al. Pancreatic cancer incidence and mor-tality patterns in China, 2011[J]. Chin J Cancer Res, 2015, 27(1): 29-37.
|
| 2 |
Wang L,Yang GH,Lu XH, et al. Pancreatic cancer mortality in China (1991-2000)[J]. World J Gastroenterol, 2003, 9(8): 1819-1823.
|
| 3 |
Shaib Y,Davila J,Naumann C, et al. The impact of curative in-tent surgery on the survival of pancreatic cancer patients: a U.S. Population-based study[J]. AM J Gastroenterol, 2007, 102(7): 1377-1382.
|
| 4 |
Burris HA 3rd,Moore MJ,Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line thera-py for patients with advanced pancreas cancer: a randomized trial[J]. J Clin Oncol, 1997, 15(6): 2403-2413.
|
| 5 |
Steins M,Thomas M,Geissler M. Erlotinib[J]. Recent Results Cancer Res, 2014, 201: 109-123.
|
| 6 |
Moore MJ,Goldstein D,Hamm J, et al. Erlotinib plus gemcitabi-ne compared with gemcitabine alone in patients with advanced pancreatic cancer:a phase Ⅲ Trial of the national Cancer Insti-tute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25(15): 1960-1966.
|
| 7 |
Benavides M,Plazas JG,Guillen C, et al. Gemcitabine(G)/erlo-tinib(E) versus gemcitabine/ erlotinib/ capecitabine(C) in the first-line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase Ⅱ b randomized study from the Spanish TTD Collaborative Group[J]. J Clin Oncol, 2014, 32: 5s suppl, abstr 4122.
|
| 8 |
Shultz D,Pai J,Graber MS, et al. A novel biomarker panel exam-ining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3[J]. J Clin Oncol, 2014, 32: 5s suppl, abstr 4133.
|
| 9 |
Shirasaka T,Shimamato Y,Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluoroura-cil by two biochemical modulators[J]. Anticancer Drugs, 1996, 7(5): 548-557.
|
| 10 |
Tatsumi K,Fukushima M,Shirasaka T, et al. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluoro-uracil degradation in rat liver extracts[J]. Jpn J Cancer Res, 1987, 78(7): 748-755.
|
| 11 |
Shirasaka T,Shimamoto Y,Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats[J]. Cancer Res, 1993, 53(17): 4004-4009.
|
| 12 |
Ueno H,Okusaka T,Furuse J, et al. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in pa-tients with metastatic pancreatic cancer[J]. Jpn J Clin Oncol, 2011, 41(8): 953-958.
|
| 13 |
Ozaka M,Matsumura Y,Ishii H, et al. Randomized phase Ⅱ study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic can-cer (Japan Clinical Cancer Research Organization PC-01 study)[J]. Cancer Chemother Pharmacol, 2012, 69(5): 1197-1204.
|
| 14 |
Sudo K,Ishihara T,Hirata N, et al. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gem-citabine for unresectable pancreatic cancer[J]. Cancer Chemother Pharmacol, 2014, 73(2):389-396.
|
| 15 |
Maeda A,Boku N,Fukutomi A, et al. Randomized phase Ⅲ trial of adjuvant chemotherapy with gemcitabine versus S-1 in pa-tients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)[J]. Jpn J Clin Oncol, 2008, 38(3): 227-229.
|
| 16 |
Ueno H,Ioka T,Ikeda M, et al. Randomized phase Ⅲ study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in pa-tients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study[J]. J Clin Oncol, 2013, 31(13): 1640-1648.
|
| 18 |
Hosein PJ,de Lima Lopes G Jr,Pastorini VH, et al. A phaseⅡtri-al of nab-Paclitaxel as second-line therapy in patients with ad-vanced pancreatic cancer[J]. Am J Clin Oncol, 2013, 36(2): 151-156.
|
| 19 |
Von Hoff DD,Ramanathan RK,Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with ad-vanced pancreatic cancer: a phase Ⅰ/Ⅱ trial[J]. J Clin Oncol, 2011, 29(34): 4548-4554.
|
| 20 |
Zhang DS,Wang DS,Wang ZQ, et al. Phase Ⅰ/Ⅱ study of albu-min-bound nab-paclitaxel plus gemcitabine administered to Chi-nese patients with advanced pancreatic cancer[J]. Cancer Che-mother Pharmacol, 2013, 71(4): 1065-1072.
|
| 21 |
Von Hoff DD,Ervin T,Arena FP, et al. Increased survival in pan-creatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369(18): 1691-1703.
|
| 22 |
Goldstein D,El-Maraghi RH,Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term sur-vival from a phase Ⅲ trial[J]. J Natl Cancer Inst, 2015, 107(2). pii: dju413.
|
| 23 |
Courtin A,Richards FM,Bapiro TE, et al. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pan-creatic cancer[J]. PLoS One, 2013, 8(6): e67330
|
| 24 |
Choi JG,Seo JH,Oh SC, et al. A phase Ⅱ trial of gemcitabine plus capecitabine for patients with advanced pancreatic cancer[J]. Cancer Res Treat, 2012, 44(2): 127-132.
|
| 25 |
Lim JY,Cho JH,Lee SJ, et al. Gemcitabine combined with capecitabine compared to gemcitabine with or without erlotinib as first-line chemotherapy in patients with advanced pancreatic can-cer[J]. Cancer Res Treat, 2015, 47(2): 266-273.
|
| 26 |
Cunningham D,Chau I,Stocken DD, et al. Phase Ⅲ randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer[J]. J Clin Oncol, 2009, 27(33): 5513-5518.
|
| 27 |
Herrmann R,Bodoky G,Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pan-creatic cancer: a randomized, multicenter, phase Ⅲ trial of the Swiss Group for Clinical Cancer Research and the Central Euro-pean Cooperative Oncology Group[J]. J Clin Oncol, 2007, 25(16): 2212-2217.
|
| 28 |
Hubner RA,Worsnop F,Cunningham D, et al. Gemcitabine plus capecitabine in unselected patients with advanced pancreatic can-cer[J]. Pancreas, 2013, 42(3): 511-515.
|
| 29 |
张洪军,张兆伟,刘峰,等.姜黄素增强胰腺癌细胞移植瘤对吉西他滨化疗敏感性的实验研究[J/CD].中华临床医师杂志:电子版, 2013, 7(21): 202-206.
|